Search / 141 results found

from
to
  • Updated

BOSTON, Nov. 29, 2021 /PRNewswire/ -- Remedium Bio, Inc., is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development. Dr. Seregin is a seasoned leader who brings more than 15 years of experience in the fields of molecular virology and gene therapy to Remedium. He has extensive experience developing viral and non-viral gene therapies in several therapeutic areas including neurodegenerative, neuromuscular, hematologic, metabolic, and gastrointestinal disorders. 

  • Updated

WESTMINSTER, Mass., Nov. 23, 2021 /PRNewswire/ -- Recovery Centers of America (RCA), a healthcare network of substance use disorder treatment facilities on the East Coast and Midwest, announced today the launch of a new specialized treatment program to assist frontline professionals facing addiction to drugs or alcohol at its central Massachusetts facility, https://recoverycentersofamerica.com/locations/westminster/ located  50 miles west of Boston.

  • Updated

BOSTON, Nov. 16, 2021 /PRNewswire-PRWeb/ -- DynamiCare Health, a digital health company for substance use disorder, has been awarded a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institute of Drug Abuse (NIDA), part of the U.S. National Institutes of Health (NIH). DynamiCare will receive up to a total of approximately $2 million over the course of three years if project milestones are met. The grant will support a large-scale randomized controlled trial to test the effectiveness of incentivizing addiction treatment providers to adopt underutilized evidence-based practices.

  • Updated

FREMONT, Calif. and WALTHAM, Mass., Nov. 11, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies London Healthcare Conference, which is taking place virtually and in-person on November 16 – 19, 2021. The fireside chat will be available to all registered participants on-demand between 3:00 a.m. ET on November 18, 2021 and 12:00 p.m. ET on November 19, 2021.

  • Updated

CAMBRIDGE, Mass., Nov. 11, 2021 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases, today announced that the company and its collaborators at Boston Children's Hospital have been selected to give an oral presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in Atlanta, GA on December 11-14, 2021. Disc will present data from studies of bitopertin, the company's orally available glycine transporter 1 (GlyT1), in preclinical models of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP).